0001171843-17-007592.txt : 20171211 0001171843-17-007592.hdr.sgml : 20171211 20171211170519 ACCESSION NUMBER: 0001171843-17-007592 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171207 FILED AS OF DATE: 20171211 DATE AS OF CHANGE: 20171211 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PEHL MICHAEL F. CENTRAL INDEX KEY: 0001677939 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-12104 FILM NUMBER: 171250149 MAIL ADDRESS: STREET 1: C/O CELGENE CORPORATION STREET 2: 86 MORRIS AVENUE CITY: SUMMIT STATE: NJ ZIP: 07901 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IMMUNOMEDICS INC CENTRAL INDEX KEY: 0000722830 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 611009366 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 300 AMERICAN RD CITY: MORRIS PLAINS STATE: NJ ZIP: 07950 BUSINESS PHONE: 9736058200 MAIL ADDRESS: STREET 1: 300 AMERICAN ROAD CITY: MORRIS PLAINS STATE: NJ ZIP: 07950 4 1 f4_pehl121117.xml OWNERSHIP DOCUMENT X0306 4 2017-12-07 0 0000722830 IMMUNOMEDICS INC IMMU 0001677939 PEHL MICHAEL F. C/O IMMUNOMEDICS, INC 300 THE AMERICAN ROAD MORRIS PLAINS NJ 07950 0 1 0 0 President and CEO Stock Options (right to buy) 11.86 2017-12-07 4 A 0 750000 0.0 A 2024-12-07 Common Stock, par value $0.01 per share 750000 750000 D Stock Options (right to buy) 11.86 2017-12-07 4 A 0 1500000 0.0 A 2024-12-07 Common Stock, par value $0.01 per share 1500000 1500000 D The reporting person was granted stock options pursuant to the Company's 2014 Long-Term Incentive Plan. The stock options vest 25% on the first anniversary of the date of grant and 2.08333% on a monthly basis thereafter. The reporting person was granted performance-based vesting stock options pursuant to the Company's 2014 Long-Term Incentive Plan. The stock options will vest (i) as to 750,000 shares (a) 25% on the first anniversary of the date of grant and 2.08333% on a monthly basis thereafter through the fourth anniversary of the date of grant (each date a "Vesting Date") and (b) subject to Immunomedics, Inc. common stock achieving a fair market value of $23.72 or higher based on the average closing price for the prior 15 consecutive trading days on such Vesting Date; and (ii) as to 750,000 shares (a) 25% on the first anniversary of the date of grant and 2.08333% on a monthly basis thereafter through the fourth anniversary of the date of grant and (b) subject to Immunomedics, Inc. common stock achieving a fair market value of $35.58 or higher based on the average closing price for the prior 15 consecutive trading days on such Vesting Date. To the extent, the performance-based vesting criteria of the stock options is not attained on an applicable Vesting Date, to the extent such performance-based vesting criteria is subsequently attained the tranche of stock options may vest on the date such criteria is met. /s/ Michael F. Pehl 2017-12-11